Nasdaq: U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated Baylor College of Medicine: A031803: Testing the Addition of Pembrolizumab to Gemcitabine for BCG-Unresponsive Non-muscle Invasive Bladder Cancer A031803: Testing the Addition of Pembrolizumab to Gemcitabine for BCG-Unresponsive Non-muscle Invasive Bladder Cancer NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...
ascopubs.org: Drug-releasing intravesical floating technology (DRIFT) for administration of sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer. Three-year median follow-up update of BGB-A317-2002-IIT: A phase 2 study of neoadjuvant tislelizumab plus gemcitabine and cisplatin in patients with cT2–T4aN0M0 muscle-invasive bladder cancer. This is ... Drug-releasing intravesical floating technology (DRIFT) for administration of sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.
gemcitabine for bladder cancer, ascopubs.org: A phase II trial of intravesical gemcitabine/docetaxel plus systemic pembrolizumab in high-risk non–muscle invasive bladder cancer unresponsive to BCG. A phase II trial of intravesical gemcitabine/docetaxel plus systemic pembrolizumab in high-risk non–muscle invasive bladder cancer unresponsive to BCG. First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for ... Credit: J&J. The New Drug Application is supported by data from cohort 2 of the single-arm, phase 2b SunRISe-1 study.
gemcitabine for bladder cancer, The device remains in the bladder and provides a sustained release of gemcitabine ... Seeking Alpha: Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. Selective bladder preservation after neoadjuvant zanidatamab combined with tislelizumab and chemotherapy in patients with HER2-positive muscle-invasive bladder cancer (HARBOR): A multicenter study.
